You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Credo Diagnostics recently received the CE mark for the coronavirus test, which can provide results in 20 minutes.
The company is also participating in a study, being conducted at Hannover Medical School, investigating the genetics of susceptibility to COVID-19.
The test is designed to detect SARS-CoV-2 nucleic acid in nasopharyngeal and oropharyngeal swab specimens from individuals suspected of having COVID-19.
The company said the revenue increase is driven primarily by growth in the life science segment due to high demand for SARS-CoV-2 molecular products.
The firm had been in stealth mode, but hopes to now attract partners to further commercialize its system for decentralized testing.
A two-stage, case-control genetic association study has implicated rare variants in the PTGIS gene in idiopathic pulmonary arterial hypertension susceptibility.
The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.
Under the guidance, only the laboratory that developed the test can perform it if the lab is CLIA-certified to perform high-complexity tests.
If the proposal is finalized, the tests will go through a less burdensome process to obtain marketing clearances.
Bringing testing closer to patients could be helpful, provided enough tests and instruments can be manufactured and distributed.
The partners will launch Zymo's DreamPrep NAP workstation to streamline DNA/RNA extraction for high-complexity testing labs running COVID-19 assays.
Under the EUA, the lab is authorized to detect SARS-CoV-2 in specimens collected from individuals suspected of having COVID-19 by their healthcare provider.
After around six months, Genetic Signatures anticipates merging its SARS-CoV-2 test with a respiratory disease testing kit.
GenomeWeb asked a number of prominent researchers in the field via email about their top picks for notable developments or achievements in genomics during the 2010s.
Color is opening a lab dedicated to SARS-CoV-2 testing and adapting its software infrastructure to enable physicians to order tests and return results.
Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
The companies have signed on to a new public-private initiative organized by Wisconsin's governor intended to increase the state's testing capacity.
The firm said the BARDA funding will support scale-up of a molecular test to facilitate management of the coronavirus pandemic cycle.
The NeuMoDx SARS-CoV-2 Test Strip can run on the firm's fully-automated mid- or high-throughput instruments.
The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.